scholarly journals Short-term effects of high-dose oral vitamin D3 in critically ill vitamin D deficient patients: a randomized, double-blind, placebo-controlled pilot study

Critical Care ◽  
2011 ◽  
Vol 15 (2) ◽  
pp. R104 ◽  
Author(s):  
Karin Amrein ◽  
Harald Sourij ◽  
Gerit Wagner ◽  
Alexander Holl ◽  
Thomas R Pieber ◽  
...  
Keyword(s):  
Vitamin D ◽  
Pilot Study ◽  
Critically Ill ◽  
Vitamin D3 ◽  
High Dose ◽  
Oral Vitamin ◽  
Short Term ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Dose Oral

scholarly journals Single high-dose oral vitamin D3 (stoss) therapy — A solution to vitamin D deficiency in children with cystic fibrosis?

2013 ◽  
Vol 12 (2) ◽  
pp. 177-182 ◽  
Author(s):  
Darren Shepherd ◽  
Yvonne Belessis ◽  
Tamarah Katz ◽  
John Morton ◽  
Penny Field ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Vitamin D ◽  
Vitamin D Deficiency ◽  
Vitamin D3 ◽  
High Dose ◽  
Oral Vitamin ◽  
Single High Dose ◽  
Dose Oral

scholarly journals High‐dose oral vitamin D3 administration increases serum and prostate levels of vitamin D metabolites safely in prostate cancer patients

2012 ◽  
Vol 26 (S1) ◽  
Author(s):  
Dennis Wagner ◽  
Theodorus Van der Kwast ◽  
Andre Dias ◽  
Laurence Klotz ◽  
Neil Fleshner ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Vitamin D ◽  
Cancer Patients ◽  
Vitamin D3 ◽  
High Dose ◽  
Vitamin D Metabolites ◽  
Oral Vitamin ◽  
Dose Oral

Effect of high-dose vitamin D3 supplementation on antibody responses against Epstein–Barr virus in relapsing-remitting multiple sclerosis

2016 ◽  
Vol 23 (3) ◽  
pp. 395-402 ◽  
Author(s):  
Egil Røsjø ◽  
Andreas Lossius ◽  
Nada Abdelmagid ◽  
Jonas C Lindstrøm ◽  
Margitta T Kampman ◽  
...  
Keyword(s):  
Vitamin D ◽  
Epstein Barr Virus ◽  
High Dose ◽  
Oral Vitamin ◽  
Barr Virus ◽  
Relapsing Remitting ◽  
Dose Oral ◽  
Epstein Barr ◽  
Antibody Levels ◽  
Relapsing Remitting Multiple Sclerosis

Background: Elevated antibody levels against Epstein–Barr virus (EBV) and a poor vitamin D status are environmental factors that may interact in relapsing-remitting multiple sclerosis (RRMS) aetiology. Objectives: To examine effects of high-dose oral vitamin D3 supplementation on antibody levels against EBV nuclear antigen 1 (EBNA1) in RRMS. Methods: Serum 25-hydroxyvitamin D3 (25(OH)D) and immunoglobulin G antibody levels against EBNA1 (whole protein and amino acid 385–420 fragment), EBV viral capsid antigen (VCA), cytomegalovirus (CMV) and varicella zoster virus (VZV) were measured in 68 RRMS patients enrolled in a 96-week randomised double-blinded placebo-controlled clinical trial of oral vitamin D3 supplementation (20,000 IU/week) (NCT00785473). Results: The mean 25(OH)D level more than doubled in the vitamin D group and was significantly higher than in the placebo group at study conclusion (123.2 versus 61.8 nmol/L, p < 0.001). Compared to the placebo group, both anti-EBNA1 protein and fragment antibody levels decreased in the vitamin D group from baseline to week 48 ( p = 0.038 and p = 0.004, respectively), but not from baseline to week 96. Vitamin D3 supplementation did not affect antibodies against VCA, CMV or VZV. Conclusion: The results indicate that high-dose oral vitamin D3 supplementation can affect humoral immune responses against the latent EBV antigen EBNA1 in RRMS.

Sign in / Sign up

Export Citation Format

Share Document